Recombinant IL-1RA / Anakinra
Rheumatoid Arthritis
Pre-clinicalActive
Key Facts
About Paras Biopharmaceuticals Finland
Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |